{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:23:08Z","timestamp":1785871388452,"version":"3.56.0"},"reference-count":19,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2015,9,22]],"date-time":"2015-09-22T00:00:00Z","timestamp":1442880000000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:sec><jats:label\/><jats:p>Adult T\u2010cell leukemia\/lymphoma (<jats:styled-content style=\"fixed-case\">ATL<\/jats:styled-content>) is a malignancy of peripheral T\u2010lymphocytes with a poor prognosis. This multicenter, two\u2010stage, single\u2010arm, phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> study assessed the efficacy and safety of bortezomib in patients with relapsed\/refractory <jats:styled-content style=\"fixed-case\">ATL<\/jats:styled-content> who received at least one regimen of chemotherapy. The primary endpoint was the best overall response rate (<jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content>), and secondary endpoints included safety, the best response by lesions, and progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>). Fifteen patients were enrolled in the first stage of this study. One partial remission (<jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content>) and five stable disease (<jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content>) were observed as the best overall responses, and <jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content> was 6.7% (95% confidence interval (C.I.) 0.17\u201031.95%). Responses according to disease sites were one complete remission (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>) in peripheral blood, two <jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content> in measurable targeted lesions, and two <jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content> in skin lesions. Progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>) was 38 (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>; 18\u2013106) days. All patients developed \u22651 adverse events (<jats:styled-content style=\"fixed-case\">AEs<\/jats:styled-content>), and 80% of patients had \u22651 grade 3\/4 <jats:styled-content style=\"fixed-case\">AEs<\/jats:styled-content>; however, no new safety findings were obtained. Although these results fulfilled the planned settings to proceed to the second stage, the coordinating committee decided to terminate this study because single agent activity did not appear to be very promising for this cohort of patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cas.12735","type":"journal-article","created":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T15:17:25Z","timestamp":1436887045000},"page":"1219-1223","source":"Crossref","is-referenced-by-count":29,"title":["A phase <scp>II<\/scp> study of bortezomib in patients with relapsed or refractory aggressive adult T\u2010cell leukemia\/lymphoma"],"prefix":"10.1111","volume":"106","author":[{"given":"Kenji","family":"Ishitsuka","sequence":"first","affiliation":[{"name":"Division of Oncology, Hematology and Infectious Diseases Fukuoka University Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atae","family":"Utsunomiya","sequence":"additional","affiliation":[{"name":"Department of Hematology Imamura Bun\u2010in Hospital Kagoshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Katsuya","sequence":"additional","affiliation":[{"name":"Division of Oncology, Hematology and Infectious Diseases Fukuoka University Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Hematology Imamura Bun\u2010in Hospital Kagoshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifusa","family":"Takatsuka","sequence":"additional","affiliation":[{"name":"Department of Hematology Imamura Bun\u2010in Hospital Kagoshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Hidaka","sequence":"additional","affiliation":[{"name":"Department of Hematology National Hospital Organization Kumamoto Medical Center Kumamoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Hematology National Hospital Organization Kumamoto Medical Center Kumamoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Yoshimitsu","sequence":"additional","affiliation":[{"name":"Division of Hematology and Immunology Center for Chronic Viral Diseases Kagoshima University Graduate School of Medical and Dental Sciences Kagoshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Tamura","sequence":"additional","affiliation":[{"name":"Division of Oncology, Hematology and Infectious Diseases Fukuoka University Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,9,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M200360200"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70202-5"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb08051.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.2428"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3472"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2843985"},{"key":"e_1_2_7_8_1","first-page":"2360","article-title":"Constitutive activation of NF\u2010kappaB in primary adult T\u2010cell leukemia cells","volume":"93","author":"Mori N","year":"1999","journal-title":"Blood"},{"key":"e_1_2_7_9_1","first-page":"1083","article-title":"Proteasome inhibitor PS\u2010341, a potential therapeutic agent for adult T\u2010cell leukemia","volume":"62","author":"Tan C","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403400"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208212"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-1701"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-175901"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780110703"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930401)71:7<2217::AID-CNCR2820710709>3.0.CO;2-8"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.394"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02986621"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412096"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.566"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcas.12735","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.12735","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cas.12735","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.12735","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T08:20:38Z","timestamp":1696234838000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.12735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1111\/cas.12735"],"URL":"https:\/\/doi.org\/10.1111\/cas.12735","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}